[1] |
Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1):6.
|
[2] |
Villanueva A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380(15):1450-1462.
|
[3] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
|
[4] |
Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204):1145-1158.
|
[5] |
Moris D, Chakedis J, Sun SH, et al. Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: a systematic review[J]. J Surg Oncol, 2018, 117(3):341-353.
|
[6] |
Chan AC, Dai JW, Chok KS, et al. Prognostic influence of spontaneous tumor rupture on hepatocellular carcinoma after interval hepatectomy[J]. Surgery, 2016, 159(2):409-417.
|
[7] |
Aoki T, Kokudo N, Matsuyama Y, et al. Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey[J]. Ann Surg, 2014, 259(3):532-542.
|
[8] |
Chan WH, Hung CF, Pan KT, et al. Impact of spontaneous tumor rupture on prognosis of patients with T4 hepatocellular carcinoma[J]. J Surg Oncol, 2016, 113(7):789-795.
|
[9] |
Chua DW, Koh YX, Allen JC, et al. Impact of spontaneous rupture on the survival outcomes after liver resection for hepatocellular carcinoma: a propensity matched analysis comparing ruptured versus non-ruptured tumors[J]. Eur J Surg Oncol, 2019, 45(9):1652-1659.
|
[10] |
Pillai A, Couri T, Charlton M. Liver allocation policies in the USA: past, present, and the future[J]. Dig Dis Sci, 2019, 64(4):985-992.
|
[11] |
Ye F, Ma D, Gong XY, et al. Development and validation of risk score for predicting spontaneous rupture of hepatocellular carcinoma[J]. Ann Surg Treat Res, 2020, 99(5):268-274.
|
[12] |
Li J, Huang L, Liu CF, et al. Risk factors and surgical outcomes for spontaneous rupture of BCLC stages A and B hepatocellular carcinoma: a case-control study[J]. World J Gastroenterol, 2014, 20(27):9121-9127.
|
[13] |
Chen Y, Guo D, Li X, et al. Predictors of spontaneous rupture of hepatocellular carcinoma and clinical outcomes following hepatectomy[J]. Front Oncol, 2022(12):820867.
|
[14] |
Nishida K, Lefor AK, Funabiki T. Rupture of hepatocellular carcinoma after transarterial chemoembolization followed by massive gastric bleeding[J]. Case Reports Hepatol, 2018:4576276.
|
[15] |
Sahu SK, Chawla YK, Dhiman RK, et al. Rupture of hepatocellular carcinoma: a review of literature[J]. J Clin Exp Hepatol, 2019, 9(2):245-256.
|
[16] |
Yoshida H, Mamada Y, Taniai N, et al. Spontaneous ruptured hepatocellular carcinoma[J]. Hepatol Res, 2016, 46(1):13-21.
|
[17] |
林坤, 高知玲, 杨冠华, 等. 基于多层螺旋CT影像特征原发性肝癌自发性破裂出血危险因素分析[J]. 中华肝胆外科杂志, 2021, 27(9):658-662.
|
[18] |
高忠嵩, 于长路, 宋德钊, 等. 肝细胞癌自发性破裂患者126例危险因素与经导管动脉栓塞治疗预后分析[J]. 中华消化杂志, 2021, 41(4):253-259.
|
[19] |
朱倩, 乔国梁, 晏建军, 等. 巴塞罗那分期A期及B期肝细胞癌自发破裂的危险因素及预后[J]. 中华肝胆外科杂志, 2015, 21(2):81-85.
|
[20] |
吴健, 童荣亮, 周杰, 等. 原发性肝癌自发性破裂的预测模型构建[J]. 浙江大学学报(医学版), 2014, 43(6):652-657.
|
[21] |
Kerdsuknirun J, Vilaichone V, Vilaichone RK. Risk factors and prognosis of spontaneously ruptured hepatocellular carcinoma in Thailand[J]. Asian Pac J Cancer Prev, 2018, 19(12):3629-3634.
|
[22] |
Tripodi A, Primignani M, Mannucci PM, et al. Changing concepts of cirrhotic coagulopathy[J]. Am J Gastroenterol, 2017, 112(2):274-281.
|
[23] |
Levi Sandri GB, Vennarecci G, Lepiane P, et al. Associating liver partition and portal vein ligation for bleeding hepatocellular carcinoma in HBV cirrhosis: a safety strategy[J]. Transl Gastroenterol Hepatol, 2017(2):20.
|
[24] |
胡章国, 蒋国兴. 乙肝病毒感染与肝癌自发性破裂相关性研究的进展[J]. 中国普外基础与临床杂志, 2013, 20(11):1325-1328.
|
[25] |
Krenkel O, Tacke F. Liver macrophages in tissue homeostasis and disease[J]. Nat Rev Immunol, 2017, 17(5):306-321.
|
[26] |
Singh Bhinder N, Zangan SM. Hepatocellular carcinoma rupture following transarterial chemoembolization[J]. Semin Intervent Radiol, 2015, 32(1):49-53.
|
[27] |
Luo P, Wu S, Yu Y, et al. Current status and perspective biomarkers in AFP negative HCC: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage[J]. Pathol Oncol Res, 2020, 26(2):599-603.
|
[28] |
Bashir NH, 鲍海华. 肝癌患者血清甲胎蛋白(AFP)水平与肿瘤大小的相关性[J]. 中国高原医学与生物学杂志, 2020, 41(2):139-144.
|